A search for synergy in the binding kinetics of Trastuzumab and Pertuzumab whole and F(ab) to Her2

Therapeutic efficacy resulting from combining Trastuzumab and Pertuzumab in the treatment of Her2 overexpressing breast cancer patients has been shown to increase patient survival. This is thought to arise from inhibition of receptor dimerization and the immune tagging of the cancer cells; however,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lua, Wai-Heng, Gan, Samuel Ken-En, Lane, David Philip, Verma, Chandra Shekhar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515203/
https://www.ncbi.nlm.nih.gov/pubmed/28721368
http://dx.doi.org/10.1038/npjbcancer.2015.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515203/
https://www.ncbi.nlm.nih.gov/pubmed/28721368
http://dx.doi.org/10.1038/npjbcancer.2015.12

Ejemplares similares